Amid buoyant expectations about the prospects of Merck & Co., Inc. and Ridgeback Biotherapeutics LP ‘s molnupiravir in COVID-19 following some standout data, two Indian firms including licensee Aurobindo Pharma Limited have sought to stop Phase III studies for the investigational oral antiviral in patients with moderate disease creating a flutter in the country.
Things were further compounded when a report quoted an unnamed official in the Indian regulatory system as saying that the...







